<DOC>
	<DOCNO>NCT02319772</DOCNO>
	<brief_summary>This 2-part , first-in-human dose-ranging study evaluate safety , tolerability pharmacokinetics escalate dos BCX4430 administer via intramuscular ( IM ) injection healthy subject . In part 1 , subject receive single dose BCX4430 ; part 2 subject receive BCX4430 7 day .</brief_summary>
	<brief_title>A Phase 1 Study Evaluate Safety , Tolerability Pharmacokinetics BCX4430</brief_title>
	<detailed_description>Part 1 study evaluate safety , tolerability pharmacokinetics single , ascend dos BCX4430 versus placebo healthy subject . Up 6 ascend dose cohort enrol sequential manner . Eight subject treat single dose study drug per dose cohort : 6 subject per cohort receive BCX4430 , 2 subject per cohort receive match placebo . Part 2 study initiate follow review available data Part 1 independent Safety Monitoring Committee Part 2 study evaluate safety , tolerability , pharmacokinetics 7 day daily dose BCX4430 versus placebo healthy subject . Up 4 ascend dose cohort treat sequential manner . Ten subject treat study drug per dose cohort ( 8 subject receive BCX4430 2 subject receive placebo per cohort ) . The planned dos dose regimen Part 2 cohort determine base upon data collect Part 1 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Hemorrhagic Fever , Ebola</mesh_term>
	<criteria>1 . Weight ≥ 50 kg ( 110 lb ) ≤ 100 kg ( 220 lb ) 2 . Body mass index ( BMI ) 1932 kg/m2 3 . Willing abstain alcohol consumption period 2 day prior study 4 . Sexually active woman child bear potential sexually active men must utilize 2 highly effective contraceptive method 5 . Abstain caffeinated beverage 6 . Normal vital sign rest 7 . Ability provide write informed consent 1 . Subjects study site employee , immediate family member study site sponsor employee 2 . Participation clinical research study within previous 90 day 3 . Any medical condition medical history , opinion investigator sponsor , would interfere subject 's ability participate study increase risk participation subject 4 . Any screening laboratory test abnormal result grade 1 ( mild ) great 5 . Abnormal ECG ( define screen baseline QTc &gt; 450 msec , PR &gt; 200 msec , ventricular and/or atrial premature contraction frequent occasional , and/or couplet higher group 6 . An abnormal cardiovascular exam include confirm elevated blood pressure screening ( systolic great 140 , diastolic great 90 ) 5 minute supine rest , tachycardia &gt; 100 bpm 5 minute supine rest 7 . Family personal history sudden death QT prolongation 8 . Use prescription , overthecounter ( OTC ) medication herbal supplement , exception acetaminophen nonoral hormonal contraception , period 7 day prior study 9 . Inadequate muscle mass receive IM injection 10 . History alcohol drug abuse within previous year , current evidence substance dependence abuse 11 . Current smoker history smoking within last 12 month 12 . Serious adverse reaction serious hypersensitivity drug 13 . Presence history clinically significant allergy require treatment , judge investigator . Hayfever allow unless active 14 . Donation loss great 400 mL blood within previous 3 month 15 . Positive serology hepatitis B surface antigen , hepatitis C antibody , human immunodeficiency virus ( HIV ) type 1 16 . Pregnant nursing female 17 . Male subject pregnant female partner</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>Ebola virus</keyword>
	<keyword>Filovirus</keyword>
</DOC>